TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving rMenB+OMV NZ Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Post-operative Wound Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CIEDs function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' response measured by HISERG scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated Hemoglobin levels (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Half-Life (t1/2) of Selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Discharge Readiness
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients receiving different types of short-term antithrombotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients taking ticagrelor with cardiovascular events after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure treatment goal achievement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL-C treatment goal achievement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in venous blood CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline DEX (self rated) to 3 weeks after beginning of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline DEX (caregiver rated) to 3 weeks after beginning of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Zoo Map Test to 1 week post test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of surgical smoke and bio-aerosols' particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Anxiety Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Edinburgh Postnatal Depression Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with clinically significant acute GHVD (Grade II or higher)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative proportion of patients with severe chemotherapy-induced thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in centre of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in centre of pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants recruited compared to number actually enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fasted Plasma Beta-alanine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastrocnemius Carnosine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Soleus Carnosine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in occurrence of cluster headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to maximum headache score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PCT value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypoxia markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Record of Severity of Problems (DRSP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Global Impression- Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hearing profile assessed through audiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language development assessed by intelligibility scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anxiety levels as measured by the State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Irritable Bowel Syndrome Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of loosening of the pins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin levels of carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with undetectable viral reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfaction With Patient's Pain Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in internal carotid artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TY-302
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicity (DLT) of TY-302
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) of TY-302 combine with Tamoxifen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Grade 3 Medically Attended Adverse Events Following Immunisation
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in post test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disease specific failure
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analog Scoring for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in postural stability during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pain Levels during Cold Pressor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pain Tolerance during Cold Pressor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Short Cortical Inhibition during Transcranial Magnetic Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Macrophage Migration Inhibitory Factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cerebral perfusion pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in nausea and vomiting from baseline to Day 2 (short term)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nausea and vomiting from baseline to Day 14(+/-1) (long term)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient's quality of life in late stage dementia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: patient's comfort of dying with dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically relevant Pleural Effusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of recanalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reperfusion slope after vascular occlusion test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Who Attended One or More PrEP Telemedicine Appointments at 3 Months Post-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Received a PrEP Medication Prescription at 3 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of posture correction girdle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTV dose coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home Blood Pressure Recording Fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physician determined target outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of toxic (non disease-related) deaths
Endpoint domain: Mortality/survival
Primary endpoint: Amygdala reactivity towards fearful faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amygdala resting state connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of symptomatic recurrent venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of clinically-relevant (i.e. major plus clinically-relevant non-major [CRNM])
Endpoint domain: Adverse events/effects
Primary endpoint: Door-to-balloon time (D2B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: changes from baseline in controlled attenuation parameters (CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful intubation attempt with ventilation of both lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subject Reported Worst Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration (Cmax) of MTC896 in the plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Acceptability of Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: difficulty to inflate and/or deflate device after IPP implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Lead Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Lead Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual intragastric content volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Responders at Week 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma lipids and lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma and serum inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual analog scale (VAS) score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax on urge incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERG function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and haematological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional outcome using DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Motor Learning (Precision)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen transport (TaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical safety measurements
Endpoint domain: Adverse events/effects
Primary endpoint: weight gain of preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of hospital stay of preterm infants
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: developing prematurity-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: rate of eosinophilic pneumonia due to daptomycin
Endpoint domain: Adverse events/effects
Primary endpoint: Median aortic diameters in aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cross-sectional aortic area/patient height ratio in aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of aneurysms with cross-sectional aortic area/patient height ratio >10 cm2/m
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success of regenerative endodontics therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first symptom of urinary tract infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean time to GI function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average speaking intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response (partial response or complete response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing biochemical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in duration of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein concentration in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Beck Depression Index (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of invasive pulmonary aspergillosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tear Protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma area under plasma concentration-time curve from time zero to time infinity post dose (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sedentary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HLA levels in the kidney graft biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Epidural Medication Consumption Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N2 Event-Related Potential Component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase of lacrimal inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Global Impressions-Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease management decision
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the selection of meal components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the consumption of meal components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WBC level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Upper Airway Closing Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Pathological Swallows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum albumin in g/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine aminotransferase in U/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aspartate aminotransferase in U/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ejaculation preservation effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Concentration of Calcium in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Concentration of 25-hydroxy Vitamin D in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Concentration of Parathyroid Hormone (PTH) in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: collar diameter/abdominal circumference ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease-Free Survival at 2 Years Post Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Disease-Free Survival at 5 Years Post Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Wounds Reaching Complete Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI activation during learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Blood Phenylalanine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak Vo2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oncologic stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Palliative surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of radical surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concordance of asthma symptom expression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Limitations of daily activities caused by asthma
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: surface EMG overflow and control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with improvement or died
Endpoint domain: Mortality/survival
Primary endpoint: Number of Decayed, Missing and Filling Teeth (DMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Decayed and Filling Surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Restoration Failure Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Burden associated with the disclosure issue
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burden associated with the secrecy issue
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-efficacy from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in emotional self-efficacy from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive reappraisal scores at baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient toxicities attributed to the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Patients with acceptable LV pacing configuration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of Self Distancing with exposure therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Self Distancing based on treatment completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With a Minimal Clinically Important Difference (MCID) in SGRQ Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in biomarkers in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes